{"id":"prednisone-and-aspirin","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal bleeding or ulceration"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression/increased infection risk"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone is a corticosteroid that binds glucocorticoid receptors to suppress T-cell activation, cytokine production, and inflammatory mediator release. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, thereby decreasing platelet aggregation and inflammation. The combination leverages both immunosuppressive and antiplatelet/anti-inflammatory effects.","oneSentence":"Prednisone suppresses immune and inflammatory responses via glucocorticoid receptor activation, while aspirin inhibits platelet aggregation and reduces inflammation through cyclooxygenase inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:02:18.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions requiring corticosteroid therapy with concurrent antiplatelet/anti-inflammatory benefit"},{"name":"Conditions requiring both immunosuppression and thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT04918524","phase":"","title":"The Clinical Features and Pregnancy Outcomes of CTD Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-09-11","conditions":"Connective Tissue Diseases, Pregnancy Related","enrollment":126},{"nctId":"NCT04976465","phase":"PHASE1","title":"Treatment and Clinical Outcomes Among SLE Patients in Pregnancy","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-01-01","conditions":"Systemic Lupus Erythematosus, Pregnancy Related","enrollment":200},{"nctId":"NCT02409147","phase":"NA","title":"Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-01","conditions":"Uterus Transplant","enrollment":""},{"nctId":"NCT04766996","phase":"PHASE4","title":"PROUD Study - Preventing Opioid Use Disorders","status":"TERMINATED","sponsor":"Emory University","startDate":"2021-05-17","conditions":"Anesthesia, Opioid Use","enrollment":57},{"nctId":"NCT05644210","phase":"","title":"Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-10-01","conditions":"Antiphospholipid Syndrome","enrollment":80},{"nctId":"NCT05578456","phase":"PHASE4","title":"Effect of Prednisone and Aspirin on IVF-ET Outcome Among Patients With Thyroid Autoimmunity","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-11-01","conditions":"Thyroiditis, Autoimmune, Infertility","enrollment":540},{"nctId":"NCT04239196","phase":"PHASE2","title":"Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA","status":"UNKNOWN","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2020-09-10","conditions":"Giant Cell Arteritis, Optic Ischaemic Neuropathy","enrollment":58},{"nctId":"NCT04544059","phase":"PHASE2","title":"Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":87},{"nctId":"NCT03671174","phase":"NA","title":"Immunosuppressant Regimens for Living Fetuses Study","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-08-02","conditions":"Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss","enrollment":420},{"nctId":"NCT02254655","phase":"PHASE2","title":"The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Chengdu PLA General Hospital","startDate":"2013-11","conditions":"Rheumatoid Arthritis","enrollment":119},{"nctId":"NCT02219191","phase":"NA","title":"Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases","status":"UNKNOWN","sponsor":"Chengdu PLA General Hospital","startDate":"2014-08","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT02990403","phase":"PHASE4","title":"The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss","status":"UNKNOWN","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2014-10","conditions":"Recurrent Pregnancy Loss","enrollment":500},{"nctId":"NCT00405756","phase":"PHASE3","title":"A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2007-01","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":459},{"nctId":"NCT00691704","phase":"PHASE2","title":"Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy","status":"COMPLETED","sponsor":"Cristina Gasparetto","startDate":"2008-08","conditions":"Multiple Myeloma","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":103,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prednisone and Aspirin","genericName":"Prednisone and Aspirin","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone suppresses immune and inflammatory responses via glucocorticoid receptor activation, while aspirin inhibits platelet aggregation and reduces inflammation through cyclooxygenase inhibition. Used for Inflammatory and autoimmune conditions requiring corticosteroid therapy with concurrent antiplatelet/anti-inflammatory benefit, Conditions requiring both immunosuppression and thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}